论文部分内容阅读
BACKGROUND: In the treatment of human non-small-cell lung cancer(NSCLC), intravenous administration makes drugs accumulate not only in the lungs but also in other organs and may undergo degradation in the systemic circulation.It is necessary to develop a carrier which can protect the drugs and effectively deliver drugs to the target site.